Madison Vaccines, Inc.

Madison Vaccines, Inc. (MVI): is a therapeutic vaccine development company. It is focused on treatments for early intervention in prostate cancer. In the US, there are 240,000 new cases of prostate cancer annually, 80,000 recurrences and 30,000 deaths. MVI has three assets: two vaccines and a companion diagnostic test. The vaccines will be targeted to patients who have been treated by surgery or radiation, and whose PSA levels begin to rise again indicating that cancer cells are still present.